(Health Korea News / Lee Chang-yong) SK Biopharmaceuticals announced through a public disclosure on the 18th that it has signed a contract to sell and supply its new epilepsy treatment drug ‘Cenobamate (US product name XCOPRI®)’ to its US subsidiary, SK Life Science.
The contract amount is 46.24247 billion won, which is about 13% of the total sales last year (about 354.9 billion won). The contract period is from July 18 to December 15.
This contract is an internal transaction to supply products to SK Life Science and is not included in sales on the consolidated financial statements.
This drug was approved by the US FDA in November 2019 under the product name ‘Xcopri’ in recognition of its efficacy in treating partial-onset epilepsy in adults. In March 2021, it also received sales approval from the European Commission (EC) and is currently on the market.
Last year, ‘Xcopri’ recorded sales of 270.8 billion won in the US, ranking first in the number of new epilepsy patient prescriptions in the local market. The company expects to record sales of 450 billion won in the US this year, a 66% increase.
‘Senobamate’ has not yet received domestic approval. SK Biopharm plans to launch it in Korea around 2025. The target indication is expected to be the same as in the US and Europe, treating partial-onset epilepsy.
The company is also conducting multinational clinical trials in eight countries, including Korea, the U.S., Australia, and Germany, to expand the age range for administering ‘Xenobamate’ from adults to children.
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
